info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Opcapone (Ongentys)
518
Article source: Seagull Pharmacy
Sep 11, 2025

Opcapone (Ongentys) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, used as an adjunctive treatment for Parkinson's disease (PD).

Indications for Opcapone (Ongentys)

Core Uses

As an adjunctive therapy to levodopa/carbidopa, it is indicated for patients with Parkinson's disease who experience "off" periods (motor symptom fluctuations).

By inhibiting the COMT enzyme, it reduces the metabolism of levodopa and prolongs its therapeutic effect, thereby improving motor fluctuation symptoms.

Dosage Forms, Specifications and Properties of Opcapone (Ongentys)

Dosage Forms and Specifications

Capsules: Available in two specifications, 25mg and 50mg.

50mg capsules: Dark blue opaque caps and dark pink opaque bodies, printed with white "OPC50" marking.

25mg capsules: Light blue opaque caps and light pink opaque bodies, printed with blue "OPC25" marking.

Ingredients and Properties

Active ingredient: Each capsule contains 25mg or 50mg of opicapone.

Excipients: Lactose, magnesium stearate, pregelatinized starch, etc.; capsule shells contain gelatin, titanium dioxide and colorants (FD&C Blue No. 2, Red No. 3).

Storage conditions: Store below 30°C (86°F) and avoid exposure to high-temperature environments.

Dosage and Administration of Opcapone (Ongentys)

Routine Dosage

Recommended adult dosage: 50mg once daily, taken orally before bedtime.

Dietary requirements: Fasting for 1 hour before and after taking the medicine to avoid the impact of food on drug absorption.

Patients with Hepatic Impairment

Moderate impairment (Child-Pugh Class B): Reduce the dosage to 25mg per day.

Severe impairment (Child-Pugh Class C): Contraindicated.

Patients with Renal Impairment

No dosage adjustment is required for mild to moderate impairment, but patients with end-stage renal disease (ESRD) should avoid using it.

Management of Missed Doses or Discontinuation

If a dose is missed, take the missed dose at the originally scheduled time on the next day; do not double the dose.

When discontinuing the medicine, monitor the patient's symptoms and gradually adjust the dosage of other dopaminergic drugs to prevent withdrawal reactions (such as high fever, confusion).

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
Standard Dosage and Administration of Sotorasib (AMG510)
Sotorasib (AMG510) is a KRASG12C inhibitor indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutation.Standard Dosage and Administration of...
What is Sotorasib (AMG510)?
Sotorasib (AMG510) is a highly selective targeted drug for the KRASG12C mutation. Developed by Amgen Inc., it received accelerated approval from the U.S. FDA in 2021 for the treatment of non-small cel...
How to Use Sotorasib (AMG510)
Sotorasib (AMG510) is a KRASG12C inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.How to Use...
Precautions for Administration of Sotorasib (AMG510)
Sotorasib (AMG510) is a KRASG12C mutation inhibitor, indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutation in patients who have receiv...
How to Use Opcapone (Ongentys)
Opcapone (Ongentys) is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor. It is used as an adjunctive treatment to levodopa/carbidopa for improving "off" period sympto...
Precautions for Opcapone (Ongentys) Use
Opcapone (Ongentys) is a selective and reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. As an adjunctive therapeutic agent to levodopa/carbidopa, it is used to improve "off&qu...
Indications for Lemborexant (Dayvigo)
Lemborexant (Dayvigo) is a selective orexin receptor antagonist used for the treatment of insomnia in adults, particularly in patients with difficulty falling asleep and/or difficulty maintaining slee...
How to Use Lemborexant (Dayvigo)
Lemborexant (Dayvigo) is a selective orexin receptor antagonist indicated for the treatment of insomnia in adults (characterized by difficulty falling asleep or sleep maintenance disorders). It promot...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved